Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dragan Cicic, MD
SELLAS Life Sciences Group, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Completed - Anhui Provincial Hospital
Hefei, Anhui, China
Completed - Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China
Withdrawn - Cancer Prevention and Treatment Center of Sun Yat Sen University
Guangzhou, Guangdong, China
Completed - Guangdong Provincial People'S Hospital
Guangzhou, Guangdong, China
Completed - Affiliated Hospital of Hebei University
Baoding, Hebei, China
Completed - Henan Cancer Hospital
Zhengzhou, Henan, China
Completed - the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Completed - the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Completed - Shengjing Hospital Affiliated To China Medical University
Shenyang, Liaoning, China
Completed - Linyi Cancer Hospital
Linyi, Shandong, China
Completed - Blood Disease Hospital, Chinese Academy of Medical Science
Tianjin, Tianjin Municipality, China
Completed - the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Completed
- O'Neal Comprehensive Cancer Center, University of Alabama
Birmingham, Alabama, United States
Recruiting - City of Hope - Phoenix
Goodyear, Arizona, United States
Recruiting - City of Hope National Medical Center
Duarte, California, United States
Recruiting - Moffitt Cancer Center
Tampa, Florida, United States
Rory Shallis, MDRecruiting - City of Hope - Atlanta
Newnan, Georgia, United States
Recruiting - City of Hope - Chicago
Zion, Illinois, United States
Recruiting - Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Terminated - Clinical Research Alliance, Inc.
Lake Success, New York, United States
Terminated - New York - Presbyterian Hospital
New York, New York, United States
Terminated - Unc School of Medicine, Division of Hematology
Chapel Hill, North Carolina, United States
Recruiting - Bon Secours St. Francis Cancer Center
Greenville, South Carolina, United States
Recruiting - Baylor Scott & White Health
Dallas, Texas, United States
Recruiting - Md Anderson
Houston, Texas, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 May 2021
- Primary completion
- 30 Dec 2026
- Completion
- 31 Dec 2027
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 160
- Registry id
- NCT04588922
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.